[go: up one dir, main page]

Xiao et al., 2020 - Google Patents

Roles of immune responses in the pathogenesis of immunorelated pancytopenia

Xiao et al., 2020

View PDF @Full View
Document ID
4383740293962335807
Author
Xiao N
Hao S
Zhang Y
Shao Z
Publication year
Publication venue
Scandinavian Journal of Immunology

External Links

Snippet

Some patients with pancytopenia do not conform to any diagnostic criteria of known haematological or non‐haematological diseases; however, they respond well to corticosteroid, high‐dose intravenous immunoglobulin and rituximab treatment. This …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Similar Documents

Publication Publication Date Title
US11944647B2 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
Yuan et al. Mesenchymal stem cell therapy induces FLT3L and CD1c+ dendritic cells in systemic lupus erythematosus patients
Liang et al. The imbalance between Foxp3+ Tregs and Th1/Th17/Th22 cells in patients with newly diagnosed autoimmune hepatitis
Xiao et al. Roles of immune responses in the pathogenesis of immunorelated pancytopenia
Wang et al. High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis
Ouyang et al. Increased interleukin-9 and CD4+ IL-9+ T cells in patients with systemic lupus erythematosus
Lougaris et al. Hyper immunoglobulin M syndrome due to CD40 deficiency: clinical, molecular, and immunological features
Zhang et al. ASIC1a induces synovial inflammation via the Ca2+/NFATc3/RANTES pathway
Gao et al. Lactoferrin-containing immunocomplexes drive the conversion of human macrophages from M2-into M1-like phenotype
d'Arbonneau et al. BAFF‐induced changes in B cell antigen receptor–containing lipid rafts in Sjögren's syndrome
BR112019017767A2 (en) compositions, articles of manufacture and methods related to dosing in cell therapy
Liu et al. Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus
Liu et al. Dysfunction of CD19+ CD24hiCD27+ B regulatory cells in patients with bullous pemphigoid
Du et al. Clinical, genetic and immunological characteristics of 40 Chinese patients with CD40 ligand deficiency
Yan et al. Developmental endothelial locus‐1 (Del‐1) antagonizes Interleukin‐17‐mediated allergic asthma
Xu et al. Distinct variations of antibody secreting cells and memory B cells during the course of Kawasaki disease
Marinelarena et al. Identification of a novel OX40L+ dendritic cell subset that selectively expands regulatory T cells
Min et al. Primary antibody deficiencies
Nishio et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non‐Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation
Erlandsson et al. IGF1R signalling is a guardian of self-tolerance restricting autoantibody production
Kim et al. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome
Figueroa‐Vega et al. Phenotypic analysis of IL‐10‐treated, monocyte‐derived dendritic cells in patients with systemic lupus erythematosus
JP2016506411A (en) TSPAN33, a candidate for antibody-targeted therapy for the treatment of B-cell Hodgkin lymphoma
Fukushima et al. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40
Pernaa et al. Heterozygous premature termination in zinc-finger domain of Krüppel-like factor 2 gene associates with dysregulated immunity